Kalypsys Completes $29M Series B

San Diego-based Kalypsys has raised $29M from Invermed Catalyst Fund, Sprout Group, Tavistock Life Sciences, Novartis BioVentures Fund, and others in a Series B funding. Kalypsys is a drug discovery company, and is a spinoff of the Genomics Institute of the Novartis Research Foundation. The company is focusing on small molecule drug candidates and is developing its pre-clinical pipeline. The company also added Kenneth Langone of Invemed Associates and Al Heller of One Equity Partners to its board. More information »